ARBEL IRIT 4

What Happened Irit Arbel, a director of Brainstorm Cell Therapeutics, was granted 120,000 restricted stock units (RSUs) on February 26, 2026. The reported acquisition price is $0.00, indicating these were an award rather than a purchase. Per the filing footnote, 50% of the RSUs vest on the grant date and the remaining 50% vest on the six-month anniversary, subject to continued employment.

Key Details

• Transaction date: 2026-02-26; Filing date (Form 4): 2026-05-29.
• Amount: 120,000 RSUs; reported acquisition price: $0.00 (award/grant).
• Vesting: 50% vests at grant; remaining 50% vests six months later, contingent on employment (per plan).
• Shares owned after transaction: not specified in the provided filing.
• Transaction code: A (award/grant).
• Timeliness: The Form 4 was filed ~3 months after the grant, which is later than the typical Form 4 two-business-day filing requirement.

Context This was an equity award (RSUs), not an open-market purchase or sale. RSU awards are typically used for compensation and retention; because 50% vested immediately, some of the award was earned at grant, while the remainder is time‑based. A late Form 4 filing does not change the economic nature of the grant but is notable for regulatory timeliness and disclosure tracking.